CN Patent

CN104721188A — 一种稳定的含苯甲酸阿格列汀的组合物

Assigned to Waterstone Pharmaceuticals Wuhan Co Ltd · Expires 2015-06-24 · 11y expired

What this patent protects

本发明涉及一种含苯甲酸阿格列汀的组合物。它包括苯甲酸阿格列汀、甘露醇、微晶纤维素、羟丙基纤维素、交联羧甲基纤维素钠和硬脂酸镁。此组合物可制成口服固体制剂，其制备方法为干法制粒或粉末直接压片，能有效地防止未知降解杂质含量的升高。因此，该组合物具有更好的临床治疗作用及临床用药安全性。

USPTO Abstract

本发明涉及一种含苯甲酸阿格列汀的组合物。它包括苯甲酸阿格列汀、甘露醇、微晶纤维素、羟丙基纤维素、交联羧甲基纤维素钠和硬脂酸镁。此组合物可制成口服固体制剂，其制备方法为干法制粒或粉末直接压片，能有效地防止未知降解杂质含量的升高。因此，该组合物具有更好的临床治疗作用及临床用药安全性。

Drugs covered by this patent

alogliptin-benzoate (ALOGLIPTIN BENZOATE)

Patent Metadata

Patent number: CN104721188A
Jurisdiction: CN
Classification: —
Expires: 2015-06-24
Drug substance claim: No
Drug product claim: No
Assignee: Waterstone Pharmaceuticals Wuhan Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.